(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Lipocine's earnings in 2026 is -$9,330,765.On average, 4 Wall Street analysts forecast LPCN's earnings for 2026 to be -$17,450,633, with the lowest LPCN earnings forecast at -$16,820,554, and the highest LPCN earnings forecast at -$17,905,751. On average, 4 Wall Street analysts forecast LPCN's earnings for 2027 to be -$13,723,313, with the lowest LPCN earnings forecast at -$15,192,758, and the highest LPCN earnings forecast at -$11,975,924.
In 2028, LPCN is forecast to generate -$10,730,162 in earnings, with the lowest earnings forecast at -$10,309,372 and the highest earnings forecast at -$11,045,755.